Therefore, inhibiting IDO1 during HSV-1 virotherapy could play dual roles by modulating the immunosuppressive TME and enhancing viral replication in the tumor cells, which provided us with the rationale to combine IDO1 inhibitor Navoximod with HSV-1 oncolytic virotherapy for HCC treatment. This evidence concerns the gene IDO1 and hepatocellular carcinoma.